Short interval of biopsy to robotic-assisted laparoscopic radical prostatectomy does not render any adverse effects on the perioperative outcomes

He, Minjun; Li, Yaohui; Xiang, Zhuoyi; Sun, Lian; Zhu, Yinghong; Hu, Xiaoyi; Guo, Jianming; Wang, Hang

doi:10.1097/md.0000000000011686

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beyond expectant management, patients with localized PCa have two primary options: radical prostatectomy (RP) or radiation therapy. RP may be conducted through laparoscopic or robot-assisted (RARP) techniques and may be performed within as little as 2 weeks from the time of biopsy [ 38 ]. A recent systematic review and meta-analysis of two randomized controlled trials and 9 prospective studies indicated no significant difference between the open, laparoscopic or RARP techniques in terms of complications, biochemical reoccurrence, urinary continence and erectile function, although RARP resulted in significantly lower blood loss [ 39 ].…”

Section: Prostate Cancer Backgroundmentioning

confidence: 99%

Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer

Shackleton

Ali

Khan

et al. 2021

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second-most common cancer in men worldwide and treatment options for patients with advanced or aggressive prostate cancer or recurrent disease continue to be of limited success and are rarely curative. Despite immune checkpoint blockade (ICB) efficacy in some melanoma, lung, kidney and breast cancers, immunotherapy efforts have been remarkably unsuccessful in PCa. One hypothesis behind this lack of efficacy is the generation of a distinctly immunosuppressive prostate tumor microenvironment (TME) by regulatory T cells, MDSCs, and type 2 macrophages which have been implicated in a variety of pathological conditions including solid cancers. In PCa, Tregs and MDSCs are attracted to TME by low-grade chronic inflammatory signals, while tissue-resident type 2 macrophages are induced by cytokines such as IL4, IL10, IL13, transforming growth factor beta (TGFβ) or prostaglandin E2 (PGE2) produced by Th2 cells. These then drive tumor progression, therapy resistance and the generation of castration resistance, ultimately conferring a poor prognosis. The biology of MDSC and Treg is highly complex and the development, proliferation, maturation or function can each be pharmacologically mediated to counteract the immunosuppressive effects of these cells. Herein, we present a critical review of Treg, MDSC and M2 involvement in PCa progression but also investigate a newly recognized type of immune suppression induced by the chronic stimulation of the sympathetic adrenergic signaling pathway and propose targeted strategies to be used in a combinatorial modality with immunotherapy interventions such as ICB, Sipuleucel-T or antitumor vaccines for an enhanced anti-PCa tumor immune response. We conclude that a strategic sequence of therapeutic interventions in combination with additional holistic measures will be necessary to achieve maximum benefit for PCa patients.

show abstract

Section: Prostate Cancer Backgroundmentioning

confidence: 99%